1. Introduction {#sec1}
===============

Premature ovarian insufficiency (POI) is currently considered the most apposite term to denote the loss of ovarian function caused by an abnormal and accelerated depletion of ovarian reserve in women before the age of forty \[[@B1]\]. It was characterized with the declining levels of normal hormonal and reproductive function \[[@B2]\]with the prevalence in the general population being approximately 1% \[[@B1]\]. POI is a frustrating gynecological endocrine disease triggered by highly heterogeneous causes, including socioeconomic status \[[@B3]\], autoimmune aspect \[[@B4]\], and prenatal ethanol exposure \[[@B5]\]. Previous studies had reported that women with POI had more medical issues than natural menopausal women, such as overall mortality \[[@B6]\], lipid disorders, cardiovascular diseases \[[@B7]\], osteoporosis \[[@B8]\], psychiatric diseases, and other adverse health complications \[[@B9],[@B10]\], which could have potentially devastating effect upon woman\'s health, physically and psychologically. Despite the fact that an increasing number of women worldwide are suffering from POI, the exact conclusions about the therapy of POI are still rare. Hormone therapy (HT), one of the most commonly methods used to treat POI, only aims to relieve the signs and symptoms of POI and may cause hepatic damage, vascular conditions, and cancer risk with long-term treatment \[[@B11]\].

Based on the traditional Chinese medicine theory, kidney deficiency and blood stasis are important pathogenesis of POI. Tonifying kidney (bushen) and activating blood (huoxue) is a traditional Chinese medicine treatment, which was widely used in the treatment of congestion-related diseases \[[@B12]--[@B14]\]. Previous researches reported that tonifying kidney (bushen) and activating blood (huoxue) treatment acts a pivotal part in the management of POI \[[@B15], [@B16]\]. Zeng et al. \[[@B17]\] found that bushen huoxue recipe was superior to HT for treating POI. A recent meta-analysis indicated bushen huoxue Chinese medicine can reduce the symptoms of patients suffering from POI \[[@B18]\]. However, the included studies were not complete, and the sample size was relatively small. Thus, we conducted this systematic review and meta-analysis for random controlled trials to evaluate the efficacy and safety of TKABP for the treatment of POI.

2. Materials and Methods {#sec2}
========================

We reported this systematic review and meta-analysis following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines \[[@B19]\]. The number of registration in PROSPERO is CRD42019148035.

2.1. Search Strategy {#sec2.1}
--------------------

Computer retrieved clinical studies databases including PubMed, Embase, Cochrane Library, Web of Science, China National Knowledge Infrastructure (CNKI), the Chinese BioMedical database (CBM), Chinese Scientific Journals Database (VIP), and the Wanfang database with no limitations on language and publication status. Each database was searched from their establishment to September 30, 2019. We made the retrieval formula according to the PICOS strategy. For Chinese databases, we took CNKI as an example, and the specific retrieval formula was SU = (Chinese medicine + traditional Chinese medicine + Chinese herb + bushen + huoxue) AND (premature ovarian failure + primary ovarian insufficiency + premature ovarian insufficiency + POI + POF) AND (randomization + randomized controlled + random grouping + RCT + clinical research). For other databases, we took PubMed as an example, and the search strategy was reported in Supplement Digital. These search terms will be precisely translated for other databases. We also manually searched the references of the original and reviewed articles for possible related studies to supplement the relevant literature.

2.2. Selection Criteria {#sec2.2}
-----------------------

### 2.2.1. Inclusion Criteria {#sec2.2.1}

The inclusion criteria include the following: (1) population: patients diagnosed with POI, regardless of ethnicity or nationality; (2) intervention: the therapy of Chinese herbal medicine tonifying kidney and activating blood was clearly stated in the trial group with no limitation in prescription name, dosage form, dosage, and course of treatment; (3) comparison: the comparison that tonifying kidney (bushen) and activating blood (huoxue) prescription only versus HT, no treatment, placebo, or sham treatment was investigated; (4) outcome: reporting the effect of TKABP for POI; and (5) study design: random controlled trial.

### 2.2.2. Exclusion Criteria {#sec2.2.2}

The exclusion criteria include the following: (1) animal experiments; (2) duplicated articles; (3) unable to get original data; (4) the composition of prescription is not clear; (5) other traditional Chinese medicine treatments such as acupuncture, edema, and massage.

2.3. Outcome Indicators {#sec2.3}
-----------------------

### 2.3.1. Primary Outcome Measures {#sec2.3.1}

Primary outcomes are the total effective rate, serum estradiol (E~2~), serum follicle-stimulating hormone (FSH), and serum luteinizing hormone (LH) levels. For studies that classified treatment effect into different grades while the total effective rate was not reported, we combined the effective grades into "total effective" for analysing.

### 2.3.2. Secondary Outcome Measures {#sec2.3.2}

The second outcomes are peak systolic velocity (PSV) of ovarian stromal blood, Kupperman index (KI) score, ovarian volume (OV), and incidence of adverse events.

2.4. Data Extraction {#sec2.4}
--------------------

Two authors (Hui-fang Li and Wen-jun Chen) independently extracted the following information by a predesigned and standardized data extraction form: first author, year of publication, sample size, age, course of disease, treatment interventions and control groups, treatment duration, and outcomes. Any conflict was resolved by a third author (Qi-hong Shen).

2.5. Quality Assessment {#sec2.5}
-----------------------

The risk of bias for the included trial was independently evaluated by two researchers (Wei-min Chen and Zhang-feng Feng) in reference to the Cochrane Handbook. We evaluated the following criteria: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessments, incomplete outcome data, selective reporting, and other biases. Each study was classified into low, high, or unclear. If there was a disagreement, we referred to the views of the third researcher (Qi-hong Shen).

2.6. GRADE Evaluation {#sec2.6}
---------------------

The quality of outcome was evaluated by GRADE (Grading of Recommendations Assessment, Development, and Evaluation) according to the following criteria: study design, risk of bias, rating inconsistency in results, rating indirectness of evidence, and others. The quality of evidence was classified as high, moderate, low, or very low.

2.7. Statistical Analysis {#sec2.7}
-------------------------

We conducted this meta-analysis by using Review Manager 5.3 statistical software. Regarding the study outcomes, relative risk (RR) with 95% confidence interval (CI) was used for binary variables, while weighted mean difference (WMD) and 95% CI were presented for continuous variables. Cochrane\'s *P* values and *I*^2^ were tested to examine heterogeneity among the studies. High heterogeneity most likely existed due to the clinical and methodological factors, so the random effect model was adopted in this meta-analysis even *I*^2^ was small. Subgroup analysis was performed based on duration treatment (3 months vs more than 3 months) and dosage form (herbal paste vs herbal decoction) for primary outcomes. Funnel plots were tested for assessing the publication bias when the number of trials ≥ 10. In addition, sensitivity analysis was performed by sequentially deleting trials to check the stability of the primary outcomes.

3. Result {#sec3}
=========

3.1. Search Results {#sec3.1}
-------------------

Initially, 2326 relevant studies were identified. After excluding duplicate studies, we scanned 1266 studies based on their abstracts and titles. Then, 51 articles were evaluated by full text. We also excluded 28 trials for the following reasons: eleven non-TKABP studies, nine articles with unclear composition of prescription, three studies were not RCT, two articles with duplicate publication of data, one article with mixed interventions of acupuncture, one article was lack of duration treatment, and another one article with unavailable full text. Eventually, 23 studies were included in our system review \[[@B15]--[@B17], [@B20]--[@B39]\]. The search process was displayed in [Figure 1](#fig1){ref-type="fig"}.

3.2. Study Characteristics {#sec3.2}
--------------------------

[Table 1](#tab1){ref-type="table"} shows the details of the included studies. Of these trials, all of them were published in China. A total of 1712 patients with POI were contained in these studies, including 881 in the TKABP group and 831 in the control group. The diagnosis of POI was clearly identified in 17 studies \[[@B15]--[@B17], [@B21]--[@B23], [@B25]--[@B27], [@B30], [@B32]--[@B36], [@B38], [@B39]\] and not mentioned in 6 studies \[[@B20], [@B24], [@B28], [@B29], [@B31], [@B37]\]. Nineteen studies were treated with pure herbal decoction \[[@B15]--[@B17], [@B20]--[@B27], [@B29]--[@B31], [@B34]--[@B36], [@B38], [@B39]\], one study was applied herbal decoction plus Chinese patent medicine \[[@B28]\], two studies were cured with herbal paste \[[@B32], [@B37]\], and one study included both herbal decoction and herbal paste groups \[[@B33]\]. Patients in the control group were all treated with HT. The treatment duration was set for 3 months in 7 studies \[[@B16], [@B17], [@B21]--[@B23], [@B28], [@B29], [@B32]--[@B35], [@B37]--[@B39]\], 6 months in 7 studies \[[@B15], [@B24]--[@B27], [@B30], [@B31]\],and 9 months in 2 studies \[[@B20], [@B36]\]. Of these 23 studies, 20 trials presented the total effective rates \[[@B15], [@B16], [@B20]--[@B29], [@B31]--[@B36], [@B38], [@B39]\]; 19 trials reported FSH, E~2~, and LH levels \[[@B15]--[@B17], [@B21], [@B22], [@B24], [@B26]--[@B28], [@B30]--[@B39]\], 2 trials reported PSV \[[@B26], [@B30]\], 7 trials mentioned KI \[[@B16], [@B21], [@B26], [@B31], [@B34], [@B35], [@B38]\], 3 trials stated OV \[[@B15], [@B30], [@B35]\], and 14 trials mentioned adverse events \[[@B15]--[@B17], [@B20]--[@B22], [@B25], [@B29], [@B31]--[@B35], [@B39]\]. The composition of prescription in the included studies is shown in Supplement [Table 1](#supplementary-material-1){ref-type="supplementary-material"}.

3.3. Risk of Bias Assessment {#sec3.3}
----------------------------

Although 23 studies mentioned randomized, just 11 clearly reported the random method (random number table) \[[@B15]--[@B17], [@B20]--[@B22], [@B25], [@B31]--[@B33], [@B37]\]. None of the trials reported any concealed allocation or blinding of patients and investigators. Three trials indicated the number and reasons of dropouts \[[@B31], [@B33], [@B35]\]; no selective reporting was reported. The risk of bias summary is shown in [Figure 2](#fig2){ref-type="fig"}.

4. Outcome Measures {#sec4}
===================

4.1. Primary Outcomes {#sec4.1}
---------------------

Twenty studies mentioned the treatment effect. TKABP led to a significantly higher total effective rate (RR: 1.10; 95% CI: 1.04, 1.17; *P* \< 0.001, *I*^2^ = 32%, [Figure 3](#fig3){ref-type="fig"}). Serum E~2~ and FSH levels were assessed in 19 trials; LH levels were measured in 17 trials. The pooled data of meta-analysis demonstrated that the E~2~ levels were significantly higher (SMD: 0.70; 95% CI: 0.14, 1.26; *P* \< 0.05, *I*^2^ = 95%, [Figure 4](#fig4){ref-type="fig"}), while FSH levels (SMD: −0.50; 95% CI: −0.81, −0.18; *P* \< 0.05, *I*^2^ = 95%, [Figure 5](#fig5){ref-type="fig"}) were significantly lower in the TKABP group. The result showed no significant difference about LH levels (SMD: −0.29; 95% CI: −0.64, 0.07; *P*=0.12, *I*^2^ = 89%, [Figure 6](#fig6){ref-type="fig"}).

4.2. Secondary Outcomes {#sec4.2}
-----------------------

Compared with controls, patients treated with TKABP had significantly lower Kupperman scores (SMD: −0.78; 95% CI: −1.24, −0.31; *P* \< 0.05, *I*^2^ = 81%, [Figure 7](#fig7){ref-type="fig"}) and significantly higher PSV of ovarian stromal blood (SMD: 0.45; 95% CI: 0.16, 0.74; *P* \< 0.05, *I*^2^ = 0%, [Figure 8](#fig8){ref-type="fig"}). No significant difference about OV was spotted between the trial and control groups (SMD: 0.07; 95% CI: −0.17, 0.31; *P*=0.56, *I*^2^ = 0%, [Figure 9](#fig9){ref-type="fig"}).

No significant difference about occurrence of ventosity was revealed (RR 1.28, 95% CI 0.43--3.87, *P*=0.67, *I*^2^ = 0%, [Figure 10](#fig10){ref-type="fig"}). Other adverse effects, including nausea, vomiting, headache, breast pain, edema, facial plaque, and vaginal bleeding, had no significantly difference reported ([Figure 10](#fig10){ref-type="fig"}).

4.3. Subgroup Analysis {#sec4.3}
----------------------

We performed subgroup analyses to further analyze the source of significant heterogeneity. Subgroup analyses showed that the total effective rate had no significant difference between patients who received herbal paste or herbal decoction (Supplement [Figure 1](#supplementary-material-1){ref-type="supplementary-material"}). However, total effective rate in patients with 3 months of treatment duration was significantly higher (Supplement [Figure 2](#supplementary-material-1){ref-type="supplementary-material"}). In addition, forest plot demonstrated that herbal paste and 3 months of treatment duration led to a significant better improvement in terms of serum E~2~, FSH, and LH levels, and the heterogeneity significantly reduced (Supplement Figures [3](#supplementary-material-1){ref-type="supplementary-material"}--[8](#supplementary-material-1){ref-type="supplementary-material"}). The results of subgroup analyses are summarized in [Table 2](#tab2){ref-type="table"}.

4.4. Publication Bias and Sensitivity Analysis {#sec4.4}
----------------------------------------------

Funnel plots for total effective rate and serum E~2~, FSH, and LH levels were in symmetric distribution, which indicated publication bias was not existed (Supplement Figures [9](#supplementary-material-1){ref-type="supplementary-material"}--[12](#supplementary-material-1){ref-type="supplementary-material"}). Sensitivity analysis was performed for the total effective rate, and the effect estimate remained unchanged, which indicated the robustness of the pooled results (Supplement Figures [1](#supplementary-material-1){ref-type="supplementary-material"}--[3](#supplementary-material-1){ref-type="supplementary-material"}).

4.5. GRADE Evaluation {#sec4.5}
---------------------

The quality of evidence was low for total effective rate, serum E~2~, FSH, and LH levels, and Kupperman score. The GRADE level of evidence was moderate for OV, PSV of ovarian stromal blood, and complications. Summary of GRADE evaluation is shown in [Table 3](#tab3){ref-type="table"}.

5. Discussion {#sec5}
=============

Our study demonstrated that TKABP increases the total effective rate of POI, improves the serum E~2~ and FSH levels, PSV of ovarian stromal blood, and Kupperman index, and decreases the incidence of adverse effects. The quality of evidence was moderate and low. In addition to the above effects, herbal paste of TKABP and 3 months treatment might be more effective.

According to TCM theory, the etiology and pathogenesis of POI are always dominated by the deficiency of kidneys, which store essence and dominate reproduction, including "qi deficiency," "yin deficiency," and "yang deficiency." Qi deficiency patients are unable to promote blood operation, yin deficiency patients with pulse path rigidity, and yang deficiency with pulse stagnation, which may lead to blood stasis. Kidney deficiency and blood stasis also affect and transform each other. Therefore, the focus of treatment is to regulate hormone levels and improve ovarian function by tonifying kidney and promoting blood circulation. Many studies whether they were clinical or animal researches have shown that Chinese nourishing kidney and activating blood herbs, such as Prepared radix rehmanniae, dodder, Chinese yam, safflower, Salvia, and Lycium barbarum, have the effect of phytoestrogen \[[@B40], [@B41]\] and also can regulate the reproductive axis in dual directions, enhance or regulate the immune function, and prevent osteoporosis \[[@B42]--[@B44]\]. In this meta-analysis, we found that TKABP could significantly accelerate the peak systolic velocity of ovarian stromal blood, which can alleviate blood stasis to improve the blood supply of ovaries.

Subgroup analysis for total effective rate and hormone levels showed that the TKABP group was better than the HT group in 3 months course studies. However, in more than 3 months course studies, there was no statistically significant difference between the two groups. It may be related to the poor long-term adherence to Chinese medicine for patients \[[@B45]\]. The study also showed that compliance of researchers in clinical trials of TCM may be affected with the extension of treatment time \[[@B46]\]. Another subgroup analysis based on dosage form showed that the total effective rate had no significant difference. However, herbal paste had a significantly better improvement of serum E~2~, FSH, and LH levels, and the heterogeneity significantly reduced, which indicated that herbal paste might be better than the herbal decoction for treating POI. The results of previous clinical studies also showed that the herbal paste had obvious advantages over the traditional decoction, such as stable property, easy preservation, convenient administration, and long-lasting effect, which led to a better compliance among patients \[[@B47]\]. However, the number of studies that reported herbal paste was really small, and we should be more careful in promoting this result.

A recent meta-analysis focused on the effect of TKABP for patients with premature ovarian failure. There are some different aspects to our study: first, the previous meta-analysis only included 12 RCTs, while 23 trials were analyzed in our study; second, some trials in the previous meta-analysis did not clearly report the ingredients of TKABP, which may cause a little bias; third, we assessed the quality for the evidence by GRADE. So, it is necessary for us to conduct this meta-analysis.

6. Limitations {#sec6}
==============

In addition, some limitations in this study should be acknowledged. First, the included studies had low quality due to an unclear allocation concealment, selective bias, attrition bias, and blinding methods, and all studies do not preestimate the sample size. Second, the ingredient of TKABP was different among studies, which might result in bias. Third, although we searched the studies without language restriction, all the publication regions were in China. Fourth, studies with negative results may have been published with a lower frequency, leading to publication bias. Fifth, the criteria for the efficacy of each study was inconsistent. As a result, the evaluation had certain subjectivity and difference, which affected the accuracy and stability of the outcome.

7. Conclusion {#sec7}
=============

In summary, our results show that TCM therapy tonifying kidney and activating blood may be a safe and effective treatment for POI and could be considered as an alternative treatment to conventional therapy. In addition, the herbal paste may be a better choice. However, due to the relatively low quality of the included studies, we should be in more caution to promote this result. We should standardize and unify the diagnosis and treatment standards, and a well-designed, multicenter, and large-sample study was needed to ensure the scientific, objective, and reliable conclusions of the research in the future clinical research so as to make the results more convincing and provide clinical evidence for the treatment of POI with TCM tonifying kidney and activating blood prescription.
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###### 

The detail of included studies.

  Studies           Sample size (*n*)   Age (*y*)   Course of disease   Intervention measures   Duration treatment (mos)   Main outcomes                                                                        
  ----------------- ------------------- ----------- ------------------- ----------------------- -------------------------- --------------------- -------------------------------------------------- ------- --- --------
  Jin, 2013         86                  88          33.25 ± 3.11        34.11 ± 3.31            147.99 ± 21.85 days        148.11 ± 21.89 days   Bushenhuoxue decoction                             A + B   6   ①②③④⑥⑧
  Xu, 2013          24                  24          31.8 ± 3.6          31.6 ± 3.7              1.5 ± 0.4 yrs              1.6 ± 0.5 yrs         Bushentiaojing decoction                           A + B   3   ①②③④⑦⑧
  Bi, 2015          50                  50          34.5 ± 3.6          33.9 ± 3.2              17.8 ± 9.4 mos             18.1 ± 9.6 mos        Bushentiaochong decoction                          A + B   9   ①⑧
  Zeng, 2019        32                  31          28.63 ± 6.49        31.06 ± 6.61            2.21 ± 1.07 yrs            2.02 ± 0.92 yrs       Huoxuezishen decoction                             E       3   ②③④⑧
  Fang, 2015        26                  26          32.6 ± 2.9          33.2 ± 3.9              12.5 ± 3.7 mos             13.3 ± 4.2 mos        Bushenhuoxue decoction                             C + D   3   ①②③④⑦⑧
  Gao, 2007         30                  30          33.033 ± 3.017      32.96 ± 4.563           18.27 ± 9.96 mos           19.23 ± 9.71 mos      Bushentiaochong decoction                          A + B   3   ①②③④⑧
  Jiang, 2013       45                  45          35.4                34.9                    2.8 yrs                    2.6 yrs               Yishenguijing decoction                            A + B   3   ①
  Li, 2016          34                  34          Not mentioned       Not mentioned           Not mentioned              Not mentioned         Bushenhuoxue decoction                             B + C   6   ①②③④
  Ma, 2015          50                  50          28.70 ± 9.53        28.21 ± 6.09            13.86 ± 7.51 mos           14.71 ± 7.20 mos      Bushen decoction                                   C       6   ①⑧
  Shen, 2013        68                  60          32.45 ± 4.16        31.68 ± 3.97            Not mentioned              Not mentioned         Zishenhuoxue decoction                             E       6   ①②③④⑤⑦
  Wang, 2010        20                  20          34.53 ± 4.32        33.72 ± 6.48            23.25 ± 13.42 mos          23.25 ± 13.42 mos     Bushenhuoxue decoction                             B + C   6   ①②③④
  Wang, 2010        48                  42          Not mentioned       Not mentioned           Not mentioned              Not mentioned         Bushentiaojing decoction + Dahuang Zhechong pill   B + C   3   ①②③④
  Wang, 2015        50                  50          33.2 ± 3.4          32.6 ± 3.5              18.2 ± 9.1 mos             19.2 ± 9.4 mos        Bushenchongtiao decoction                          B + C   3   ①⑧
  Xia, 2019         30                  30          37.13 ± 4.45        35.4 ± 4.89             3.03 ± 1.58 yrs            3.33 ± 1.74 yrs       Bushenhuoxue decoction                             B + C   6   ②③⑤⑥
  Xu, 2014          30                  30          36.5 ± 2.8          36.0 ± 2.7              1.5 ± 0.4 yrs              1.6 ± 0.5 yrs         Bushentiaojing decoction                           A + B   6   ①②③④⑦⑧
  Xu, 2017          34                  34          38.03 ± 0.83        37.53 ± 0.96            1.91 ± 0.75 yrs            1.94 ± 0.74 yrs       Bushentiaojing paste                               A + B   3   ①②③④⑧
  Xu, 2017          23                  23          37.52 ± 1.16        37.78 ± 1.09            1.91 ± 0.73 yrs            1.96 ± 0.71 yrs       Bushentiaojing decoction                           A + B   3   ①②③④⑧
  Xu, 2017          23                  23          38.04 ± 1.11        37.78 ± 1.09            2.08 ± 0.85 yrs            1.96 ± 0.71 yrs       Bushentiaojing paste                               A + B   3   ①②③④⑧
  Xu, 2012          23                  23          29.1 ± 3.4          28.7 ± 3.1              1.6 ± 0.3 yrs              1.7 ± 0.4 yrs         Bushentiaojing decoction                           F       3   ①②③④⑦⑧
  Yi, 2008          22                  20          34.9 ± 3.5          33.8 ± 3.9              18.7 ± 6.9 mos             19.1 ± 7.9 mos        Tiaojingkangshuai                                               
                                                                                                                                                  Decoction                                         A + B   3   ①②③⑥⑦⑧
  Zhao, 2014        36                  24          33.04 ± 4.3         32.89 ± 4.03            1.90 ± 1.52 yrs            2.18 ± 1.36 yrs       Fuchao decoction                                   B + C   9   ①②③④
  Zhao, 2019        39                  39          23.55 ± 5.55        23.64 ± 5.44            1.61 ± 0.61 yrs            1.58 ± 0.22 yrs       Bushentiaojing paste                               C + D   3   ②③④
  Zhong, 2019       38                  38          34.12               34.10                   9.29 ± 4.35 mos            9.30 ± 4.40 mos       Zishenhuoxue decoction                             A + B   3   ①②③④⑦
  Zhong Wei, 2019   20                  20          36.0 ± 2.02         36.2 ± 1.94             6.15 ± 1.93 mos            6.10 ± 1.62 mos       Bushenhuoxue decoction                             C + D   3   ①②③④⑧

Abbreviation: mos, months; yrs, years; A, conjugated estrogen; B, medroxyprogesterone acetate (MPA); C, estradiol valerate; D, progesterone capsule; E, Climen (combination of estradiol valerate and cyproterone acetate); F, Marvelon (combination of desogestrel and ethinylestradiol). ① The total effective rate; ② serum estradiol (E~2~) levels; ③ serum follicle-stimulating hormone (FSH) levels; ④ serum luteinizing hormone (LH) levels; ⑤ peak systolic velocity (PSV) of ovarian stromal blood; ⑥ ovarian volume (OV); ⑦ Kupperman index (KI) score; and ⑧ adverse events.

###### 

Subgroup analysis for primary outcomes.

                           Studies   MD/SMD/RR   95 CI            *P*      *I* ^*2*^ (%)
  ------------------------ --------- ----------- ---------------- -------- ---------------
  *Total effective rate*                                                    
  3 M                      14        1.14        (1.06, 1.22)     \<0.05   21
  \<3 M                    6         1.04        (0.97, 1.02)     0.24     21
  *E* ~*2*~                                                                 
  3 M                      12        1.19        (0.44, 1.94)     \<0.05   95
  \<3 M                    7         −0.18       (−0.94, 0.57)    0.63     94
  *FSH*                                                                     
  3 M                      12        −0.53       (−0.86, −0.91)   \<0.05   80
  \<3 M                    7         −0.46       (1.10, 0.19)     0.16     93
  *LH*                                                                      
  3 M                      11        −0.62       (−0.99, −0.26)   \<0.05   81
  \<3 M                    6         0.37        (−0.09, 0.83)    0.11     84
  *Total effective rate*                                                    
  Herbal decoction         19        1.09        (1.03, 1.15)     \<0.05   27
  Herbal paste             2         1.10        (1.04, 1.17)     \<0.05   0
  *E* ~*2*~                                                                 
  Herbal decoction         17        0.29        (−0.21, 0.79)    0.26     94
  Herbal paste             3         3.00        (2.32, 3.67)     \<0.05   59
  *FSH*                                                                     
  Herbal decoction         17        −0.46       (−0.82, −0.09)   \<0.05   88
  Herbal paste             3         −0.73       (−1.03, −0.44)   \<0.05   0
  *LH*                                                                      
  Herbal decoction         15        −0.19       (−0.59, 0.21)    0.36     90
  Herbal paste             3         −0.85       (−1.14, −0.55)   \<0.05   0

###### 

Summary of meta-analysis results and grade evaluation.

  Index                          Number of included studies   SMD/MD/RR (95% CI)     *P* value   *I* ^2^ value (%)   GRADE
  ------------------------------ ---------------------------- ---------------------- ----------- ------------------- --------------
  Total effective rate           20                           1.10 (1.04, 1.17)      \<0.05      32                  ⊕⊕○○Low
  *E* ~2~                        19                           0.70 (0.14, 1.26)      \<0.05      95                  ⊕⊕○○Low
  FSH                            19                           −0.50 (−0.81, −0.18)   \<0.05      87                  ⊕⊕○○Low
  LH                             17                           −0.29 (−0.64, 0,09)    0.12        89                  ⊕⊕○○Low
  Ovarian volume                 3                            0.07 (−0.17, 0.31)     0.56        0                   ⊕⊕⊕○Moderate
  Kupperman score                7                            −0.78 (−1.24, -0.31)   \<0.05      81                  ⊕⊕○○Moderate
  PSV of ovarian stromal blood   2                            0.45 (0.16, 0.74)      \<0.05      0                   ⊕⊕⊕○Moderate
  Nausea                         3                            0.02 (0.00, 0.11)      \<0.05      0                   ⊕⊕⊕○Moderate
  Vomiting                       3                            0.03 (0.01, 0.16)      \<0.05      0                   ⊕⊕⊕○Moderate
  Ventosity                      5                            1.28 (0.42, 3.87)      0.67        0                   ⊕⊕⊕○Moderate
  Headache                       5                            0.25 (0.09, 0.65)      \<0.05      0                   ⊕⊕⊕○Moderate
  Breast pain                    8                            0.12 (0.06, 0.24)      \<0.05      0                   ⊕⊕⊕○Moderate
  Edema                          3                            0.15 (0.03, 0.80)      \<0.05      0                   ⊕⊕⊕○Moderate
  Vaginal bleeding               4                            0.17 (0.09, 0.36)      \<0.05      0                   ⊕⊕⊕○Moderate

[^1]: Academic Editor: Gioacchino Calapai
